Skip to main content
SpringerLink
Log in

Use of Consciousness-Enhancing Medications in the Traumatic Brain Injury Patient

  • Chapter
  • First Online:
Controversies in Severe Traumatic Brain Injury Management

  • 877 Accesses

Abstract

After traumatic brain injury (TBI), patients often experience an altered level of consciousness for some period of time, and deeply altered levels of consciousness may be classified as comatose or vegetative states. Some patients do not fit either of these categories, due to some level of preservation of self-awareness, and are defined as being in a minimally conscious state; patients may progress to this state from coma or vegetative state after a TBI. Understanding the criteria for each of these altered states is important for prognostication purposes. While a large proportion of patients with prolonged coma after a TBI will “awaken” within 1 year, many researchers have focused on utilization of pharmaceutical agents to hasten recovery of consciousness due to the propensity for complications and other deleterious issues associated with prolonged coma. However, as with all medications, the medications used have a side-effect profile that could certainly play a harmful role in recovery. In addition, limited data are available to suggest that these medications actually do aid TBI patients in their recovery. The goal of this chapter is to discuss the available evidence for conscious-enhancing medications for this use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Posner JB, Plum F. Plum and posner’s diagnosis of stupor and coma. 4th ed. Oxford: Oxford University Press; 2007.

    Google Scholar 

  2. Jennett B, Plum F. Persistent vegetative state after brain damage. A syndrome in search of a name. Lancet. 1972;1(7753):734–7.

    Article  CAS  PubMed  Google Scholar 

  3. Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI, et al. The minimally conscious state: definition and diagnostic criteria. Neurology. 2002;58(3):349–53.

    Article  PubMed  Google Scholar 

  4. Giacino JT, Kalmar K. Diagnostic and prognostic guidelines for the vegetative and minimally conscious states. Neuropsychol Rehabil. 2005;15(3–4):166–74.

    Article  PubMed  Google Scholar 

  5. Lombardi F, Taricco M, De Tanti A, Telaro E, Liberati A. Sensory stimulation for brain injured individuals in coma or vegetative state. Cochrane Database Syst Rev 2002(2):CD001427.

    Google Scholar 

  6. Kline AE, Yan HQ, Bao J, Marion DW, Dixon CE. Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neurosci Lett. 2000;280(3):163–6.

    Article  CAS  PubMed  Google Scholar 

  7. Kline AE, Massucci JL, Marion DW, Dixon CE. Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J Neurotrauma. 2002;19(4):415–25.

    Article  PubMed  Google Scholar 

  8. Wagner AK, Kline AE, Ren D, Willard LA, Wenger MK, Zafonte RD, et al. Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury. Behav Brain Res. 2007;181(2):200–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wagner AK, Drewencki LL, Chen X, Santos FR, Khan AS, Harun R, et al. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury. J Neurochem. 2009;108(4):986–97.

    Article  CAS  PubMed  Google Scholar 

  10. Wagner AK, Sokoloski JE, Chen X, Harun R, Clossin DP, Khan AS, et al. Controlled cortical impact injury influences methylphenidate-induced changes in striatal dopamine neurotransmission. J Neurochem. 2009;110(3):801–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Leary JB, Bondi CO, LaPorte MJ, Carlson LJ, Radabaugh HL, Cheng JP, et al. The therapeutic efficacy of environmental enrichment and methylphenidate alone and in combination after controlled cortical impact injury. J Neurotrauma. 2017;34(2):444–50.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rau TF, Kothiwal AS, Rova AR, Brooks DM, Poulsen DJ. Treatment with low-dose methamphetamine improves behavioral and cognitive function after severe traumatic brain injury. J Trauma Acute Care Surg. 2012;73(2 Suppl 1):S165–72.

    Article  CAS  PubMed  Google Scholar 

  13. Rau TF, Kothiwal AS, Rova AR, Brooks DM, Rhoderick JF, Poulsen AJ, et al. Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats. Exp Neurol. 2014;253:31–40.

    Article  CAS  PubMed  Google Scholar 

  14. Rau T, Ziemniak J, Poulsen D. The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:231–6.

    Article  CAS  Google Scholar 

  15. Phelps TI, Bondi CO, Ahmed RH, Olugbade YT, Kline AE. Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits. J Neurotrauma. 2015;32(8):590–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chandler MC, Barnhill JL, Gualtieri CT. Amantadine for the agitated head-injury patient. Brain Inj. 1988;2(4):309–11.

    Article  CAS  PubMed  Google Scholar 

  17. Andersson S, Berstad J, Finset A, Grimsmo J. Amantadine in cognitive failure in patients with traumatic head injuries. Tidsskr Nor Laegeforen. 1992;112(16):2070–2.

    CAS  PubMed  Google Scholar 

  18. Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49–53.

    Article  PubMed  Google Scholar 

  19. Zafonte RD, Watanabe T, Mann NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj. 1998;12(7):617–21.

    Article  CAS  PubMed  Google Scholar 

  20. Gwynette MF, Beck B, VandenBerg A, Stocking N. Under arrest: the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury. J Clin Psychopharmacol. 2015;35(1):102–4.

    Article  PubMed  Google Scholar 

  21. Wu TS, Garmel GM. Improved neurological function after amantadine treatment in two patients with brain injury. J Emerg Med. 2005;28(3):289–92.

    Article  PubMed  Google Scholar 

  22. Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, et al. Effects of the dopaminergic agent and nmda receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and d2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (pet). Brain Inj. 2005;19(7):471–9.

    Article  CAS  PubMed  Google Scholar 

  23. Green LB, Hornyak JE, Hurvitz EA. Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. Am J Phys Med Rehabil. 2004;83(12):893–7.

    Article  PubMed  Google Scholar 

  24. Hughes S, Colantonio A, Santaguida PL, Paton T. Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury. Brain Inj. 2005;19(14):1197–206.

    Article  PubMed  Google Scholar 

  25. Saniova B, Drobny M, Kneslova L, Minarik M. The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm (Vienna). 2004;111(4):511–4.

    Article  CAS  Google Scholar 

  26. Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil. 2005;20(5):450–63.

    Article  PubMed  Google Scholar 

  27. Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol. 2006;21(10):879–85.

    Article  PubMed  Google Scholar 

  28. Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13(11):863–72.

    Article  CAS  PubMed  Google Scholar 

  29. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002;17(4):300–13.

    Article  PubMed  Google Scholar 

  30. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366(9):819–26.

    Article  CAS  PubMed  Google Scholar 

  31. Hammond FM, Bickett AK, Norton JH, Pershad R. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. 2014;29(5):391–9.

    Article  PubMed  Google Scholar 

  32. Hammond FM, Sherer M, Malec JF, Zafonte RD, Whitney M, Bell K, et al. Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma. 2015;32(16):1230–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Leone H, Polsonetti BW. Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? J Clin Pharm Ther. 2005;30(2):101–4.

    Article  CAS  PubMed  Google Scholar 

  34. Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother. 2008;42(2):247–52.

    Article  CAS  PubMed  Google Scholar 

  35. Williams SE. Amantadine treatment following traumatic brain injury in children. Brain Inj. 2007;21(9):885–9.

    Article  PubMed  Google Scholar 

  36. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75(7):711–21.

    Article  CAS  PubMed  Google Scholar 

  37. Weinberg RM, Auerbach SH, Moore S. Pharmacologic treatment of cognitive deficits: a case study. Brain Inj. 1987;1(1):57–9.

    Article  CAS  PubMed  Google Scholar 

  38. Hornyak JE, Nelson VS, Hurvitz EA. The use of methylphenidate in paediatric traumatic brain injury. Pediatr Rehabil. 1997;1(1):15–7.

    Article  CAS  PubMed  Google Scholar 

  39. Worzniak M, Fetters MD, Comfort M. Methylphenidate in the treatment of coma. J Fam Pract. 1997;44(5):495–8.

    CAS  PubMed  Google Scholar 

  40. Francisco GE, Ivanhoe CB. Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report. Am J Phys Med Rehabil. 1996;75(1):63–5.

    Article  CAS  PubMed  Google Scholar 

  41. Grønborg P, Liljegren J, Jansen J. Paradoxical effect of methylphenidate in the treatment of a patient with severe traumatic brain injury. Ugeskr Laeger. 2009;171(26):2201–2.

    PubMed  Google Scholar 

  42. Reynolds JC, Rittenberger JC, Callaway CW. Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest. Resuscitation. 2013;84(6):818–24.

    Article  CAS  PubMed  Google Scholar 

  43. Wroblewski BA, Leary JM, Phelan AM, Whyte J, Manning K. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry. 1992;53(3):86–9.

    CAS  PubMed  Google Scholar 

  44. Al-Adawi S, Burke DT, Dorvlo AS. The effect of methylphenidate on the sleep-wake cycle of brain-injured patients undergoing rehabilitation. Sleep Med. 2006;7(3):287–91.

    Article  PubMed  Google Scholar 

  45. Gualtieri CT, Evans RW. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj. 1988;2(4):273–90.

    Article  CAS  PubMed  Google Scholar 

  46. Speech TJ, Rao SM, Osmon DC, Sperry LT. A double-blind controlled study of methylphenidate treatment in closed head injury. Brain Inj. 1993;7(4):333–8.

    Article  CAS  PubMed  Google Scholar 

  47. Mooney GF, Haas LJ. Effect of methylphenidate on brain injury-related anger. Arch Phys Med Rehabil. 1993;74(2):153–60.

    CAS  PubMed  Google Scholar 

  48. Plenger PM, Dixon CE, Castillo RM, Frankowski RF, Yablon SA, Levin HS. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil. 1996;77(6):536–40.

    Article  CAS  PubMed  Google Scholar 

  49. Johansson B, Wentzel AP, Andréll P, Odenstedt J, Mannheimer C, Rönnbäck L. Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain. Brain Inj. 2014;28(3):304–10.

    Article  CAS  PubMed  Google Scholar 

  50. Johansson B, Wentzel AP, Andréll P, Mannheimer C, Rönnbäck L. Methylphenidate reduces mental fatigue and improves processing speed in persons suffered a traumatic brain injury. Brain Inj. 2015;29(6):758–65.

    Article  CAS  PubMed  Google Scholar 

  51. Johansson B, Wentzel AP, Andréll P, Rönnbäck L, Mannheimer C. Long-term treatment with methylphenidate for fatigue after traumatic brain injury. Acta Neurol Scand. 2017;135(1):100–7.

    Article  CAS  PubMed  Google Scholar 

  52. McAllister TW, Zafonte R, Jain S, Flashman LA, George MS, Grant GA, et al. Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with ptsd and/or traumatic brain injury. Neuropsychopharmacology. 2016;41(5):1191–8.

    Article  CAS  PubMed  Google Scholar 

  53. Lee H, Kim SW, Kim JM, Shin IS, Yang SJ, Yoon JS. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol. 2005;20(2):97–104.

    Article  CAS  PubMed  Google Scholar 

  54. Alban JP, Hopson MM, Ly V, Whyte J. Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Am J Phys Med Rehabil. 2004;83(2):131–7. quiz 138-141, 167

    Article  PubMed  Google Scholar 

  55. Willmott C, Ponsford J, Olver J, Ponsford M. Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. J Rehabil Med. 2009;41(7):585–7.

    Article  PubMed  Google Scholar 

  56. Moein H, Khalili HA, Keramatian K. Effect of methylphenidate on icu and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin Neurol Neurosurg. 2006;108(6):539–42.

    Article  PubMed  Google Scholar 

  57. Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil. 1997;76(6):440–50.

    Article  CAS  PubMed  Google Scholar 

  58. Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004;83(6):401–20.

    Article  PubMed  Google Scholar 

  59. Kaelin DL, Cifu DX, Matthies B. Methylphenidate effect on attention deficit in the acutely brain-injured adult. Arch Phys Med Rehabil. 1996;77(1):6–9.

    Article  CAS  PubMed  Google Scholar 

  60. Williams SE, Ris MD, Ayyangar R, Schefft BK, Berch D. Recovery in pediatric brain injury: is psychostimulant medication beneficial? J Head Trauma Rehabil. 1998;13(3):73–81.

    Article  CAS  PubMed  Google Scholar 

  61. Mahalick DM, Carmel PW, Greenberg JP, Molofsky W, Brown JA, Heary RF, et al. Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg. 1998;29(3):121–6.

    Article  CAS  PubMed  Google Scholar 

  62. Ekinci O, Direk M, Gunes S, Teke H, Ekinci N, Yıldırım F, et al. Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems. Brain and Development. 2017;39(4):327–36.

    Article  PubMed  Google Scholar 

  63. Willmott C, Ponsford J. Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial. J Neurol Neurosurg Psychiatry. 2009;80(5):552–7.

    Article  CAS  PubMed  Google Scholar 

  64. Kim YH, Ko MH, Na SY, Park SH, Kim KW. Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study. Clin Rehabil. 2006;20(1):24–30.

    Article  PubMed  Google Scholar 

  65. Dymowski AR, Ponsford JL, Owens JA, Olver JH, Ponsford M, Willmott C. The efficacy and safety of extended-release methylphenidate following traumatic brain injury: a randomised controlled pilot study. Clin Rehabil. 2017;31(6):733–41.

    Article  PubMed  Google Scholar 

  66. McDonald BC, Flashman LA, Arciniegas DB, Ferguson RJ, Xing L, Harezlak J, et al. Methylphenidate and memory and attention adaptation training for persistent cognitive symptoms after traumatic brain injury: a randomized, placebo-controlled trial. Neuropsychopharmacology. 2017;42(9):1766–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Huang CH, Huang CC, Sun CK, Lin GH, Hou WH. Methylphenidate on cognitive improvement in patients with traumatic brain injury: a meta-analysis. Curr Neuropharmacol. 2016;14(3):272–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Kraus MF. Neuropsychiatric sequelae of stroke and traumatic brain injury: the role of psychostimulants. Int J Psychiatry Med. 1995;25(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  69. Kajs-Wyllie M. Ritalin revisited: does it really help in neurological injury? J Neurosci Nurs. 2002;34(6):303–13.

    Article  PubMed  Google Scholar 

  70. Siddall OM. Use of methylphenidate in traumatic brain injury. Ann Pharmacother. 2005;39(7–8):1309–13.

    Article  CAS  PubMed  Google Scholar 

  71. Whyte J, Vaccaro M, Grieb-Neff P, Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehabil. 2002;17(4):284–99.

    Article  PubMed  Google Scholar 

  72. Lee HB, Lyketsos CG, Rao V. Pharmacological management of the psychiatric aspects of traumatic brain injury. Int Rev Psychiatry. 2003;15(4):359–70.

    Article  PubMed  Google Scholar 

  73. Jin C, Schachar R. Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies. CNS Spectr. 2004;9(3):217–26.

    Article  PubMed  Google Scholar 

  74. Forsyth R, Jayamoni B, Paine T, Mascarenhas S. Monoaminergic agonists for acute traumatic brain injury. Cochrane Database Syst Rev. 2006;(1):CD003984.

    Google Scholar 

  75. Tenovuo O. Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury. Curr Opin Neurol. 2006;19(6):528–33.

    Article  CAS  PubMed  Google Scholar 

  76. Maksimowski MB, Tampi RR. Efficacy of stimulants for psychiatric symptoms in individuals with traumatic brain injury. Ann Clin Psychiatry. 2016;28(3):156–66.

    PubMed  Google Scholar 

  77. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003;18(2):177–95.

    Article  PubMed  Google Scholar 

  78. Arciniegas DB, McAllister TW. Neurobehavioral management of traumatic brain injury in the critical care setting. Crit Care Clin. 2008;24(4):737–65. viii

    Article  PubMed  Google Scholar 

  79. Krieger D, Hansen K, McDermott C, Matthews R, Mitchell R, Bollegala N, et al. Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. NeuroRehabilitation. 2003;18(3):205–8.

    PubMed  Google Scholar 

  80. Temple MJ. Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury. J R Army Med Corps. 2003;149(1):54–5.

    Article  CAS  PubMed  Google Scholar 

  81. Freeman T, High WM. Treatment of a patient with traumatic brain injury-related severe self-injurious behavior. J Head Trauma Rehabil. 2009;24(4):292–6.

    Article  PubMed  Google Scholar 

  82. Trémeau F, Mauro CJ, Shope C, Riber LM, Dhami S, Citrome L. High dose quetiapine in the treatment of psychosis due to traumatic brain injury: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(1):280–1.

    Article  Google Scholar 

  83. Viana BM, Prais HA, Nicolato R, Caramelli P. Posttraumatic brain injury psychosis successfully treated with olanzapine. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(1):233–5.

    Article  CAS  Google Scholar 

  84. Richardson JK. Psychotic behavior after right hemispheric cerebrovascular accident: a case report. Arch Phys Med Rehabil. 1992;73(4):381–4.

    Article  CAS  PubMed  Google Scholar 

  85. Silva JA, Leong GB, Wine DB. Misidentification delusions, facial misrecognition, and right brain injury. Can J Psychiatr. 1993;38(4):239–41.

    Article  CAS  Google Scholar 

  86. Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports. Ann Clin Psychiatry. 1997;9(2):105–7.

    Article  CAS  PubMed  Google Scholar 

  87. Umansky R, Geller V. Olanzapine treatment in an organic hallucinosis patient. Int J Neuropsychopharmacol. 2000;3(1):81–2.

    Article  PubMed  Google Scholar 

  88. Noe E, Ferri J, Trenor C, Chirivella J. Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. Behav Neurol. 2007;18(1):7–11.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Michals ML, Crismon ML, Roberts S, Childs A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol. 1993;13(3):198-203.

    Article  PubMed  Google Scholar 

  90. American Psychiatric Association. DSM-5 task force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

    Book  Google Scholar 

  91. Wilkinson R, Meythaler JM, Guin-Renfroe S. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj. 1999;13(12):1025–31.

    Article  CAS  PubMed  Google Scholar 

  92. Kadyan V, Colachis SC, Depalma MJ, Sanderson JD, Mysiw WJ. Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. Brain Inj. 2003;17(7):631–7.

    Article  PubMed  Google Scholar 

  93. Bellamy CJ, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma. 2009;66(3):954–8.

    Article  PubMed  Google Scholar 

  94. Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil. 1985;66(1):30–4.

    CAS  PubMed  Google Scholar 

  95. Stanislav SW. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997;11(5):335–41.

    Article  CAS  PubMed  Google Scholar 

  96. Kim E, Bijlani M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2006;18(4):547–9.

    Article  CAS  PubMed  Google Scholar 

  97. Levy M, Berson A, Cook T, Bollegala N, Seto E, Tursanski S, et al. Treatment of agitation following traumatic brain injury: a review of the literature. NeuroRehabilitation. 2005;20(4):279–306.

    PubMed  Google Scholar 

  98. Lombard LA, Zafonte RD. Agitation after traumatic brain injury: considerations and treatment options. Am J Phys Med Rehabil. 2005;84(10):797–812.

    Article  PubMed  Google Scholar 

  99. Luauté J, Plantier D, Wiart L, Tell L, SOFMER Group. Care management of the agitation or aggressiveness crisis in patients with tbi. Systematic review of the literature and practice recommendations. Ann Phys Rehabil Med. 2016;59(1):58–67.

    Article  PubMed  Google Scholar 

  100. Plantier D, Luaute J, SOFMER Group. Drugs for behavior disorders after traumatic brain injury: systematic review and expert consensus leading to French recommendations for good practice. Ann Phys Rehabil Med. 2016;59(1):42–57.

    Article  CAS  PubMed  Google Scholar 

  101. Jha A, Weintraub A, Allshouse A, Morey C, Cusick C, Kittelson J, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil. 2008;23(1):52–63.

    Article  PubMed  Google Scholar 

  102. Kaiser PR, Valko PO, Werth E, Thomann J, Meier J, Stocker R, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology. 2010;75(20):1780–5.

    Article  CAS  PubMed  Google Scholar 

  103. Sheng P, Hou L, Wang X, Huang C, Yu M, Han X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8(12):e81802.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Menn SJ, Yang R, Lankford A. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension. J Clin Sleep Med. 2014;10(11):1181–91.

    PubMed  PubMed Central  Google Scholar 

  105. Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. 2001;82(3):311–5.

    Article  CAS  PubMed  Google Scholar 

  106. Munakomi S, Bhattarai B, Mohan Kumar B. Role of bromocriptine in multi-spectral manifestations of traumatic brain injury. Chin J Traumatol. 2017;20(2):84–6.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Whyte J, Vaccaro M, Grieb-Neff P, Hart T, Polansky M, Coslett HB. The effects of bromocriptine on attention deficits after traumatic brain injury: a placebo-controlled pilot study. Am J Phys Med Rehabil. 2008;87(2):85–99.

    Article  PubMed  Google Scholar 

  108. Haig AJ, Ruess JM. Recovery from vegetative state of six months’ duration associated with sinemet (levodopa/carbidopa). Arch Phys Med Rehabil. 1990;71(13):1081–3.

    CAS  PubMed  Google Scholar 

  109. Wolf AP, Gleckman AD. Sinemet and brain injury: functional versus statistical change and suggestions for future research designs. Brain Inj. 1995;9(5):487–93.

    Article  CAS  PubMed  Google Scholar 

  110. Lal S, Merbtiz CP, Grip JC. Modification of function in head-injured patients with sinemet. Brain Inj. 1988;2(3):225–33.

    Article  CAS  PubMed  Google Scholar 

  111. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998;12(1):77–80.

    Article  CAS  PubMed  Google Scholar 

  112. Whelan FJ, Walker MS, Schultz SK. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry. 2000;12(3):131–5.

    Article  CAS  PubMed  Google Scholar 

  113. Richer E, Tell L. Indications, efficacy and tolerance of drug therapy in view of improving recovery of consciousness following a traumatic brain injury. Ann Readapt Med Phys. 2003;46(4):177–83.

    Article  CAS  PubMed  Google Scholar 

  114. Arciniegas DB, Silver JM. Pharmacotherapy of posttraumatic cognitive impairments. Behav Neurol. 2006;17(1):25–42.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Chew E, Zafonte RD. Pharmacological management of neurobehavioral disorders following traumatic brain injury--a state-of-the-art review. J Rehabil Res Dev. 2009;46(6):851–79.

    Article  PubMed  Google Scholar 

  116. Writer BW, Schillerstrom JE. Psychopharmacological treatment for cognitive impairment in survivors of traumatic brain injury: a critical review. J Neuropsychiatry Clin Neurosci. 2009;21(4):362–70.

    Article  CAS  PubMed  Google Scholar 

  117. Sivan M, Neumann V, Kent R, Stroud A, Bhakta BB. Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review. Clin Rehabil. 2010;24(2):110–21.

    Article  PubMed  Google Scholar 

  118. Cossu G. Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery. Br J Neurosurg. 2014;28(2):187–98.

    Article  PubMed  Google Scholar 

  119. Napolitano E, Elovic EP, Qureshi AI. Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury. Med Sci Monit. 2005;11(6):RA212–20.

    PubMed  Google Scholar 

  120. Frenette AJ, Kanji S, Rees L, Williamson DR, Perreault MM, Turgeon AF, et al. Efficacy and safety of dopamine agonists in traumatic brain injury: a systematic review of randomized controlled trials. J Neurotrauma. 2012;29(1):1–18.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Penn State University Milton S. Hershey Medical Center, Hershey, PA, USA

    Justin R. Davanzo MD & Shelly D. Timmons MD, PhD, FACS, FAANS

Authors
  1. Justin R. Davanzo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shelly D. Timmons MD, PhD, FACS, FAANS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shelly D. Timmons MD, PhD, FACS, FAANS .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Penn State University Milton S. Hershey Medical Center, Hershey, PA, USA

    Shelly D. Timmons

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Davanzo, J.R., Timmons, S.D. (2018). Use of Consciousness-Enhancing Medications in the Traumatic Brain Injury Patient. In: Timmons, S. (eds) Controversies in Severe Traumatic Brain Injury Management. Springer, Cham. https://doi.org/10.1007/978-3-319-89477-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-89477-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-89476-8

  • Online ISBN: 978-3-319-89477-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation